Category: General

ABcann Granted Australian Import License

SHARE THIS POST NAPANEE, ON, January 18, 2018 (GLOBE NEWSWIRE) – ABCANN GLOBAL CORPORATION (TSXV: ABCN) (“ABcann” or the “Company”) is pleased to announce that its wholly-owned subsidiary, ABcann Australia Pty Ltd. (“ABcann Australia”), has received an import license from the Federal Office of Drug Control in Australia. ABcann continues to work with government and its industry partners in Australia to develop exclusive programs targeting physician networks. Following receipt of any necessary approvals, including the approval of the TSX Venture Exchange, ABcann intends to supply medicinal cannabis to the Australian market via the Australian Department of Health’s TGA (Therapeutic Goods Administration) Special Access Scheme. “This import license is a key milestone towards generating revenue through ABcann’s network of physicians, pharmacists and patients, and advancing the use of medical cannabis,” commented Barry Fishman, Chief Executive Officer of ABcann. “We view Australia as an important emerging market for medical cannabis and I look forward to meeting with our strategic partners and stakeholders in Australia later this month to further discuss opportunities there.” “Attainment of this license is one of several important steps we have taken over the last six months to cement key relationships with strategic partners in industry and government. ABcann Australia is committed to providing Australian patients with high quality medicinal cannabis products,” said Henry Pinskier, MD, Chairman of ABcann Australia. About ABcann: ABcann holds production and sales licenses...

Read More

Vitality Biopharma Submits Orphan Drug Designation Request to FDA for Flagship THC Prodrug VITA-100

SHARE THIS POST Treatment of pediatric ulcerative colitis will be pursued using targeted cannabinoid therapy that avoids drug psychoactivity LOS ANGELES, CA – ( January 17, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to announce it has submitted an orphan drug designation request for VITA-100 to the U.S. Food & Drug Administration (FDA). Upon approval, VITA-100 would be designated as an orphan drug for the treatment of pediatric ulcerative colitis (UC), a form of pediatric inflammatory bowel disease. The U.S. Orphan Drug Act (ODA) of January 1983 is meant to encourage development of drugs for rare diseases, and review by the FDA’s Office of Orphan Products Development can expedite the evaluation and eventual market approval of products that demonstrate significant promise for the treatment of these conditions. Vitality Biopharma’s gut-targeted cannabosides enable delivery of THC without psychoactivity or intoxication, which may enable more widespread use of cannabinoids for treatment of pediatric digestive disorders. The Company has already completed studies that demonstrate the efficacy of cannabosides for treatment of preclinical models of colitis. Cannabosides were able to reduce weight loss, decrease damage to the colon, and markedly improve gastrointestinal health compared to the placebo controls. “In young children,...

Read More

Alliance Growers Update on 2017 Audited Financials

SHARE THIS POST January 17, 2018 – Vancouver, B.C. – Alliance Growers Corp. (CSE: ACG; FWB: 1LA; WKN: A2DFYX) (“Alliance Growers” or the “Company”) reports that today the company will file its financial statements, management discussion and analysis, and certification of annual filings for the year ended August 31st, 2017 (collectively, the “2017 Financials”). The British Columbia Securities Commission has been contacted and it is expected that the cease trade order against the Company and securities will be lifted on Friday, January 19, 2018 to allow trading to resume on the Canadian Securities Exchange (“CSE”). The Company would also like to inform investors that our email “info@alliancegrowers.com” has been upgraded and we will now be able to respond to queries. Commenting on 2017 Financials, Dennis Petke, Alliance Growers President and CEO states “Alliance went through its growing pains in the last two years and is now going to the next level thanks to our recent successful financing and continued support of our loyal shareholders.  Going forward we now have an appropriate budget to meet our continuous disclosure obligations in a more timely manner.  We are very pleased to enter 2018 with many exciting projects that we will be able to execute upon with our current financing proceeds and with our next $5 million raise expected to be completed in the coming weeks.  Alliance Growers has many exciting prospects on...

Read More

Future Farm Raises Over $2.5 Million through Voluntary Warrant and Option Exercises

SHARE THIS POST January 17, 2018 – Vancouver, British Columbia – Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (OTCQB: FFRMF) is pleased to announce that $2,553,092 has been raised to date through the voluntary conversion of both its $0.35 and $0.37 warrants and through the exercise of options. The $0.35 per share warrants expired on January 11, 2018, however Shareholders may still convert their $0.37 per share warrants into Future Farm’s common stock until March 7, 2018. Shareholders wishing to exercise their warrants are asked to contact the Company by following the instructions below: Enquiries by email: Belinda Tyldesley at closingbellservices@gmail.com Original Warrant Exercise Forms and payment by way of certified cheque or bank draft payable to “Future Farm Technologies Inc.” should be delivered to #510-580 Hornby Street, Vancouver, BC V63 3B6 or by wire transfer in Canadian funds to Future Farm Technologies Inc.  Wire instructions will be provided upon request. For further information, contact William Gildea, Director, at 617.834.9467. On behalf of the Board, Future Farm Technologies Inc. William Gildea, CEO & Chairman About Future Farm Future Farm Technologies Inc. is a Canadian company with projects throughout North America including California, Florida and Maryland. The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various...

Read More

Kush Bottles Reports First Fiscal Quarter 2018 Results

SHARE THIS POST Revenues Increased 258% Year-over-Year to approximately $8.85 million SANTA ANA, Calif. – January 16, 2018 – Kush Bottles, Inc. (OTCQB: KSHB), a leading provider of packaging, supplies, vaporizers, accessories and branding solutions for the regulated cannabis industry, today reported financial results for its first fiscal quarter of 2018, for the period ended November 30, 2017. Fiscal First Quarter Financial Summary Revenue was up 258% Year-over-Year to $8.85 million. Gross margins were 30%, compared with 34% in the prior year period, which is attributed to increased business in the lower margin vaporizer product segment. Net income, including $382,000 in non-cash stock compensation, $202,000 in depreciation and amortization expense and $1.9 million in SG&A, was $94,615 compared to net loss of $161,000 in the fiscal first quarter of 2017. Cash balance was $5.5 million as of November 30, 2017 compared to $0.9 million at August 31, 2017. Working capital was $8.6 million as of November 30, 2017 compared to $3.4 million at August 31, 2017. Nick Kovacevich, Chairman & CEO Nick Kovacevich, Chairman and CEO of Kush Bottles, commented, “We entered fiscal 2018 with excellent momentum as we saw the impact of the strategic initiatives implemented throughout 2017 start to take hold. Revenues for the first fiscal quarter of 2018 reached approximately $8.85 million, representing a 258% increase compared with fiscal Q1 2017. This strength in the business led to net profits of $94,615 in...

Read More

Grey Cloak (OTCQB: GRCK) Announces Strategic Partnership With Canbiola, Inc

SHARE THIS POST LAS VEGAS, NV, Jan. 16, 2018 (GLOBE NEWSWIRE) — – Grey Cloak Tech Inc., (GRCK) today announced a strategic partnership with Canbiola, Inc. (CANB) to list their products on the CBD.co marketplace.   “We’re pleased to be doing a Joint Venture with CBD.co, for the simple reason CBD.Co does the rigorous vetting of all of the products that reside on their site, that’s a creating incredible Marketplace for CBD vendors that qualify,” said Marco Alfonsi, CEO of Canbiola Inc. (CANB) in a recent interview with Grey Cloak Tech CEO Patrick Stiles. “It’s important to have our two companies work together to create a marketplace that’s amenable to everybody’s thought process moving forward because at the end of the day it’s all about sales. If you can’t sell a product and can’t get the word out there, you get stifled,” said Marco Alfonsi. To kick off the relationship, Grey Cloak’s Chief Executive Officer, Patrick Stiles, interviewed Canbiola’s CEO, Marco Alfonsi, and Medical Advisory Board Member, Dr. Robert Kornfield, discussing the partnership and the Canbiola products. These interviews can be found at cbd.co/canbiola  The video interviews are part of CBD.co’s brand new initiative, CBD TV, to create video content around CBD and educate consumers on the different brands and products. CBD TV includes interviews, product reviews and education related to hemp and CBD. Canbiola announced in the last quarter...

Read More